. LRIG1 antibody validation. The LRIG1 antibody was used to immunostain (brown) formalin-fixed and paraffin embedded (FFPE) cell pellets using an automatic Ventana staining machine. Cell nuclei were counterstained with DAPI (blue). (A) LRIG1-negative 293T cells. Both of the LRIG1 loci were deleted in 293T cells using CRISPR-Cas9 technology. Thereafter, cells were cloned and confirmed to be LRIG1-deficient by western blotting. Presented is an LRIG1-deficient clone named 293T-clone 3. No LRIG1 immunostaining could be observed among the LRIG1-negative cells. (B) LRIG1-positive 293T cells. LRIG1-deficient 293T-clone 3 cells were transduced with a doxycycline-inducible LRIG1 allele followed by treatment with doxycyline. LRIG1 expression was confirmed by western blotting. Clearly, some of the doxycycline-treated cells exhibited positive LRIG1 immunostaining, which was consistent with flow cytometric analyses revealing that a minority of the cells had been transduced with the LRIG1 expression construct. LRIG1, leucine-rich repeats and immunoglobulin-like domains 1.
. Validation of LMO7 antibodies. A total of 16.7 mg of lysates from COS-7 (ATCC, Manssas, VA, USA) cells transfected with 2 µg LMO7-FLAG-pcDNA3.1 (15) were loaded per well on a 3-8% Tris-acetate gel and transferred to a LF PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). As a control, the same amount of lysates from non-transfected cells were used. Membranes were incubated with the following primary antibodies: (ACTN05 mouse anti-actin; dilution 1:4,000; cat. no. ab3280; Abcam, Cambridge, UK), HPA020923 rabbit anti-LMO7 (Sigma-Aldrich; Merck KGaA), 0.8 µg/ml, according to the manufacturer's protocol or rabbit anti-LMO7-1250, 1.2 µg/ml. Secondary antibodies used were: IRDye goat anti-rabbit 680RD 1:15,000 and IRDye 800CW goat anti-mouse 1:15,000 (LI-COR Biosciences, Lincoln, NE, USA). Western blot analysis of COS-7 lysates stained with antibody (A) LMO7 (cat. no. HPA020923; Sigma-Aldrich; Merck KGaA) and (B) LMO7-1250.
